UPDATE: Morgan Stanley Reiterates Overweight Rating, Raises PT on ResMed
In a report published Wednesday, Morgan Stanley reiterated its Overweight rating on ResMed (NYSE: RMD), and slightly raised its price target from $32.95 to $33.37.
Morgan Stanley noted, “While recovery in US device growth was observed, ROW device growth looked likely to continue deceleration from double-digit growth in FY11 to the low-single-digit growth reported in Q212 – the positive surprise of +7.0% in Q312 was impressive against the trend of ASP pressure in France and changes to PSG payment in Germany, and the stock is now priced for the positive level to continue.”
ResMed closed on Tuesday at $31.56.
Latest Ratings for RMD
|Jan 2017||JP Morgan||Upgrades||Neutral||Overweight|
|Sep 2016||Bank of America||Upgrades||Neutral||Buy|
|Sep 2016||JP Morgan||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.